S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
Introducing MarketBeat All Access (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
66,000% upside on tiny biotech? (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Greek authorities rescue 91 migrants from river islet on border with Turkey
66,000% upside on tiny biotech? (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
Introducing MarketBeat All Access (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
66,000% upside on tiny biotech? (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Greek authorities rescue 91 migrants from river islet on border with Turkey
66,000% upside on tiny biotech? (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
Introducing MarketBeat All Access (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
66,000% upside on tiny biotech? (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Greek authorities rescue 91 migrants from river islet on border with Turkey
66,000% upside on tiny biotech? (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
Introducing MarketBeat All Access (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
66,000% upside on tiny biotech? (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Greek authorities rescue 91 migrants from river islet on border with Turkey
66,000% upside on tiny biotech? (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
NASDAQ:PTCT

PTC Therapeutics (PTCT) Stock Forecast, Price & News

$44.12
+0.62 (+1.43%)
(As of 06/2/2023 ET)
Compare
Today's Range
$43.06
$44.40
50-Day Range
$41.16
$59.10
52-Week Range
$25.01
$59.84
Volume
678,224 shs
Average Volume
1.04 million shs
Market Capitalization
$3.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.93

PTC Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.36 Rating Score
Upside/​Downside
20.0% Upside
$52.93 Price Target
Short Interest
Bearish
7.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.38
Upright™ Environmental Score
News Sentiment
0.90mentions of PTC Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$7.97 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.21) to ($3.00) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

544th out of 980 stocks

Pharmaceutical Preparations Industry

271st out of 485 stocks


PTCT stock logo

About PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. is a biopharmaceutical company. It engages in discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTCT Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
14 Analysts Have This to Say About PTC Therapeutics
PTC Therapeutics (NASDAQ:PTCT) PT Lowered to $48.00
PTC Therapeutics (NASDAQ:PTCT) PT Raised to $57.00
See More Headlines

PTCT Price History

PTCT Company Calendar

Last Earnings
4/27/2023
Today
6/04/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PTCT
Employees
1,410
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$52.93
High Stock Price Forecast
$66.00
Low Stock Price Forecast
$37.00
Forecasted Upside/Downside
+20.0%
Consensus Rating
Hold
Rating Score (0-4)
2.36
Research Coverage
11 Analysts

Profitability

Net Income
$-559,020,000.00
Pretax Margin
-77.95%

Debt

Sales & Book Value

Annual Sales
$698.80 million
Book Value
($6.17) per share

Miscellaneous

Free Float
70,259,000
Market Cap
$3.27 billion
Optionable
Optionable
Beta
0.42

Key Executives

  • Matthew B. KleinMatthew B. Klein
    President, Chief Executive Officer & Director
  • Emily Hill
    Chief Financial Officer
  • Neil Gregory AlmsteadNeil Gregory Almstead
    Chief Technical Operations Officer
  • Ellen Welch
    Chief Scientific Officer
  • Mark Elliott BouldingMark Elliott Boulding
    Chief Legal Officer & Executive Vice President













PTCT Stock - Frequently Asked Questions

Should I buy or sell PTC Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 1 sell rating, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PTCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PTCT, but not buy additional shares or sell existing shares.
View PTCT analyst ratings
or view top-rated stocks.

What is PTC Therapeutics' stock price forecast for 2023?

11 analysts have issued 12 month price objectives for PTC Therapeutics' shares. Their PTCT share price forecasts range from $37.00 to $66.00. On average, they anticipate the company's share price to reach $52.93 in the next year. This suggests a possible upside of 20.0% from the stock's current price.
View analysts price targets for PTCT
or view top-rated stocks among Wall Street analysts.

How have PTCT shares performed in 2023?

PTC Therapeutics' stock was trading at $38.17 at the beginning of the year. Since then, PTCT stock has increased by 15.6% and is now trading at $44.12.
View the best growth stocks for 2023 here
.

When is PTC Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our PTCT earnings forecast
.

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its quarterly earnings data on Thursday, April, 27th. The biopharmaceutical company reported ($1.88) earnings per share for the quarter, missing analysts' consensus estimates of ($1.64) by $0.24. The biopharmaceutical company had revenue of $220.38 million for the quarter, compared to the consensus estimate of $200.48 million. The business's revenue was up 48.2% compared to the same quarter last year. During the same period last year, the firm posted ($1.78) earnings per share.

What guidance has PTC Therapeutics issued on next quarter's earnings?

PTC Therapeutics updated its FY 2023 earnings guidance on Thursday, April, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $940.00M-$1.00 billion, compared to the consensus revenue estimate of $866.89 million.

What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO?

24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees.

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD).

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

Who are PTC Therapeutics' major shareholders?

PTC Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include RTW Investments LP (9.56%), Wellington Management Group LLP (9.43%), Armistice Capital LLC (3.94%), State Street Corp (3.92%), Price T Rowe Associates Inc. MD (2.32%) and Macquarie Group Ltd. (2.21%). Insiders that own company stock include Allan Steven Jacobson, Christine Marie Utter, David P Southwell, Dawn Svoronos, Emily Luisa Hill, Emma Reeve, Eric Pauwels, Mark Elliott Boulding, Matthew B Klein, Matthew B Klein, Neil Gregory Almstead, Stephanie Okey and Stuart Walter Peltz.
View institutional ownership trends
.

How do I buy shares of PTC Therapeutics?

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PTC Therapeutics' stock price today?

One share of PTCT stock can currently be purchased for approximately $44.12.

How much money does PTC Therapeutics make?

PTC Therapeutics (NASDAQ:PTCT) has a market capitalization of $3.27 billion and generates $698.80 million in revenue each year. The biopharmaceutical company earns $-559,020,000.00 in net income (profit) each year or ($7.89) on an earnings per share basis.

How many employees does PTC Therapeutics have?

The company employs 1,410 workers across the globe.

How can I contact PTC Therapeutics?

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The official website for the company is www.ptcbio.com. The biopharmaceutical company can be reached via phone at (908) 222-7000, via email at ehill@ptcbio.com, or via fax at 908-222-7231.

This page (NASDAQ:PTCT) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -